[go: up one dir, main page]

AR107067A1 - Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación - Google Patents

Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Info

Publication number
AR107067A1
AR107067A1 ARP160103873A ARP160103873A AR107067A1 AR 107067 A1 AR107067 A1 AR 107067A1 AR P160103873 A ARP160103873 A AR P160103873A AR P160103873 A ARP160103873 A AR P160103873A AR 107067 A1 AR107067 A1 AR 107067A1
Authority
AR
Argentina
Prior art keywords
formulations
ovulation
methods
reproductive cycle
control
Prior art date
Application number
ARP160103873A
Other languages
English (en)
Inventor
Roberto Sammartino Daniel
Andrs Colman Juan
Original Assignee
Proinvet Innovations S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proinvet Innovations S A filed Critical Proinvet Innovations S A
Publication of AR107067A1 publication Critical patent/AR107067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones de hormonas, unidades de dosificación que incluyen las formulaciones de hormonas y métodos de uso, relacionados con una formulación de liberación controlada que incluye hormonas, por ejemplo, progesterona. Las formulaciones y métodos son para controlar el ciclo reproductivo y/o la ovulación de un mamífero hembra, por ejemplo, para favorecer la ovulación de un mamífero hembra o sincronizar la ovulación o el celo de un grupo de mamíferos hembra. Además, las formulaciones son para incrementar la probabilidad de que un mamífero hembra quede preñado luego de su inseminación.
ARP160103873A 2015-12-18 2016-12-16 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación AR107067A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/066863 WO2017105512A1 (en) 2015-12-18 2015-12-18 Formulations and methods for controlling the reproductive cycle and ovulation

Publications (1)

Publication Number Publication Date
AR107067A1 true AR107067A1 (es) 2018-03-14

Family

ID=59057228

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103873A AR107067A1 (es) 2015-12-18 2016-12-16 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación
ARP220100962A AR125357A2 (es) 2015-12-18 2022-04-18 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220100962A AR125357A2 (es) 2015-12-18 2022-04-18 Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación

Country Status (13)

Country Link
US (1) US10898432B2 (es)
EP (1) EP3389690B1 (es)
CN (1) CN108367046B (es)
AR (2) AR107067A1 (es)
AU (1) AU2016369500A1 (es)
CL (1) CL2018001635A1 (es)
CO (1) CO2018006041A2 (es)
ES (1) ES2893121T3 (es)
MX (1) MX2018007354A (es)
NZ (1) NZ744338A (es)
PE (1) PE20181290A1 (es)
UY (1) UY37033A (es)
WO (2) WO2017105512A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CN111281877A (zh) * 2018-11-22 2020-06-16 南京诺瑞特医药科技有限公司 神经活性类固醇的新制剂
CN110215433A (zh) * 2019-07-16 2019-09-10 苏州素仕生物科技有限公司 一种氯前列醇注射液及其制备方法
JP2023508606A (ja) * 2019-12-23 2023-03-02 オーガスタ ユニバーシティ リサーチ インスティチュート，インコーポレイテッド 排卵を誘発し、黄体期支持を提供するプロゲステロン製剤
CN111346054A (zh) * 2020-03-10 2020-06-30 上海图珐医药科技有限公司 一种黄体酮乳剂型注射剂及其制备方法
CN115137697B (zh) * 2021-08-17 2024-08-23 浙江科瑞特生物科技有限公司 一种d-氯前列醇钠注射液及其制备方法、应用
WO2024218609A1 (en) * 2023-04-18 2024-10-24 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599227A (en) 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6028057A (en) 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
EP1900283A3 (en) * 1998-03-23 2010-02-10 General Mills, Inc. Encapsulation of components into edible products
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2399695A1 (en) 2000-03-22 2001-09-27 The Secretary Of State For Defence Pharmaceutical composition for administration to mucosal surfaces
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
PT1443912E (pt) * 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
AU2003208679A1 (en) 2002-02-08 2003-09-02 Advanced Animal Technology Limited Control of a biological function
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20090036384A1 (en) * 2005-12-02 2009-02-05 Parnell Laboratories (Aust) Pty Limited Increasing pregnancy rates
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
RU2009116933A (ru) * 2006-10-05 2010-11-10 Панацея Биотек Лтд. (In) Новые депо-композиции для инъекций и способ изготовления указанных композиций
MXPA06015172A (es) 2006-12-20 2009-04-17 Gonzalo Urbiola Verdejo Solucion inyectable de progesterona de liberacion prolongada para uso veterinario y proceso de obtencion del mismo.
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
CN101427993A (zh) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
CN102291992A (zh) * 2009-01-26 2011-12-21 哈尔·维特 同期发情制剂和有效的无cidr方案
US9011908B2 (en) * 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
CN101856361A (zh) 2010-06-08 2010-10-13 瓜州县龙兴畜牧产业发展有限公司 一种用于母牛发情调控的孕酮复合制剂
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN103284955A (zh) 2012-03-02 2013-09-11 上海市计划生育科学研究所 长效孕激素缓释注射埋植剂及其制备方法
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
RU2020140867A (ru) * 2012-06-18 2021-06-10 Терапьютиксмд, Инк. Капсулы с растворимым эстрадиолом для интравагинального введения
CN103585103A (zh) 2012-08-15 2014-02-19 杭州伟智生物医药科技有限公司 一种含tpgs的性激素微纳米人体注射乳剂及其制备方法
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation

Also Published As

Publication number Publication date
EP3389690A4 (en) 2019-08-28
CO2018006041A2 (es) 2018-07-10
NZ744338A (en) 2020-03-27
ES2893121T3 (es) 2022-02-08
BR112017018319A2 (pt) 2018-04-17
AU2016369500A1 (en) 2018-06-07
CL2018001635A1 (es) 2018-08-17
MX2018007354A (es) 2018-11-09
EP3389690A1 (en) 2018-10-24
WO2017105512A1 (en) 2017-06-22
CN108367046A (zh) 2018-08-03
AR125357A2 (es) 2023-07-12
WO2017106618A1 (en) 2017-06-22
CN108367046B (zh) 2021-12-21
US20180289614A1 (en) 2018-10-11
EP3389690B1 (en) 2021-07-07
UY37033A (es) 2017-07-31
US10898432B2 (en) 2021-01-26
PE20181290A1 (es) 2018-08-07

Similar Documents

Publication Publication Date Title
CO2018006041A2 (es) Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación
AR082266A1 (es) Microparticula inyectable de liberacion controlada
GT201500233A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
ES2948324R1 (es) Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (Estetrol monohidrato)
BR112015012453A8 (pt) métodos e usos para sincronizar o tempo de ovulação e de inseminação em uma leitoa
BR112017011905A2 (pt) dispositivo intrauterino, sistema e método para tratamento de cavidade uterina
BR112016010427A2 (pt) proteína para prevenir infecção por mycoplasma spp., composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para preparar antígeno solúvel
AR106505A1 (es) Tratamiento de la oligo-ovulación relacionada con esteatosis hepática
CR20160176A (es) Sistema de administración intrauterina
MX2016013449A (es) Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada.
BR112016022463A2 (pt) método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica
MX2018006026A (es) Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
UY35584A (es) Composición farmacéutica, su uso y régimen de administración para contracepción programada
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
CL2016000217A1 (es) Nueva composición veterinaria inyectable para la sincronización del desove en peces
CL2015003013A1 (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
UY36168A (es) FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH
UY35662A (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
AR101582A1 (es) Tratamiento de tejido mamario con óxido nítrico

Legal Events

Date Code Title Description
FG Grant, registration